Mechanisms of hypoglycemia-associated authonomic failure

描述（由申请人提供）：1型糖尿病（T1DM）的强化血糖控制与明显的健康益处相关。然而，对于大多数患者来说，维持接近正常的血糖仍然是一个难以实现的目标，这在很大程度上是由于低血糖水平（低血糖）的风险。T1DM患者由于有缺陷的反调节反应（CR）而容易发生低血糖，其特征是：1)即将发生低血糖时胰高血糖素释放不足；2)额外的低血糖相关自主神经衰竭（HAAF）和运动相关自主神经衰竭（EAAF），在反复发作低血糖或运动后减弱交感肾上腺对低血糖的反应，并降低其他CR；3)低血糖无意识，降低了引发行为反应（如进食）的症状阈值。因此，T1DM患者的低血糖风险阻碍了理想的胰岛素治疗，导致血糖控制不理想。我们的实验室已经探索了一种新的方法，通过将HAAF/EAAF的机制转化为潜在的治疗方法来调节CR到低血糖，从而提高CR。我们之前已经证明，通过阿片受体阻断可以预防T1DM患者的HAAF。由于肾上腺素能激活也对低血糖CR有调节作用，因此我们假设连接阿片能和肾上腺素能系统的共同机制负责HAAF和EAAF的发展。我们的具体目标是：研究阿片受体和/或肾上腺素能受体的激活是否调节人类HAAF， 2。2 .确定负责调节HAAF/EAAF的肾上腺素能反应成分及其与阿片能系统的关联；进行初步的临床试验来检查

DESCRIPTION (provided by applicant): Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health benefits. However, maintaining near-normal glycemia remains an elusive goal for most patients, in large part owing to the risk of low glucose levels (hypoglycemia). T1DM patients are susceptible to hypoglycemia due to defective counterregulatory responses (CR) characterized by: 1) deficient glucagon release during impending hypoglycemia; 2) additional hypoglycemia-associated autonomic failure (HAAF) and exercise-associated autonomic failure (EAAF) that blunt the sympathoadrenal responses to hypoglycemia following repeated episodes of hypoglycemia or exercise as well as degrading other CR; and 3) hypoglycemia unawareness, lowering the threshold for symptoms that trigger behavioral responses (e.g. eating). Thus, the risk of hypoglycemia in T1DM impedes ideal insulin treatment and leads to suboptimal glycemic control. Our lab has explored a new approach of enhancing CR by translating mechanisms responsible for HAAF/EAAF into potential therapeutics to modulate the CR to hypoglycemia. We have previously demonstrated that HAAF can be prevented in T1DM patients by opioid receptor blockade. Since adrenergic activation has also a modulatory effect on hypoglycemia CR, we thus hypothesize that a common mechanism linking opioidergic and adrenergic systems is responsible for the development of HAAF and EAAF. Our specific aims are to 1. Examine whether activation of ¿-opioid receptors, and/or adrenergic receptors, regulate HAAF in humans, 2. Establish the components of the adrenergic response responsible for modulating HAAF/EAAF and their association with the opioidergic system, and 3. Perform a preliminary clinical trial to examine the efficacy of chronic opioid receptor blockade in preventing HAAF in patients with T1DM. Correction or improvement of hypoglycemia counterregulation and restoring hypoglycemia awareness in patients with T1DM would represent an enormous step forward in the management of these patients, including preventing morbidities or death.